Nearly 30 generic drugmakers in Asia, Africa and the Middle East will make cheap versions of Merck & Co’s COVID-19 pill, under a landmark U.N.-backed deal to give poorer nations wider access to a drug seen as a weapon in fighting the pandemic.
Featured Posts
Q&A with Pfizer’s Mikael Dolsten - Med Ad News’ 2021 Company of the Year Pfizer has led the global war against the COVID-19 pandemic with the vaccine Comirnaty in partnership with BioNTech. To find out about some of the other significant products and pipeline assets in Pfizer’s arsenal, Med Ad News talked to Mikael Dolsten, M.D., Ph.D., Chief Scientific Officer and President, Worldwide Research, Development and Medical.
The Biden administration is preparing for future variants of COVID-19, White House chief of Staff Ron Klain told MSNBC in an interview that aired on January 20 as the Omicron-related wave of cases appeared to be easing in parts of the United States.
Zymeworks provided a corporate update that included a string of clinical trial news. Additionally, 10 members of Zymeworks’ senior management team are leaving the clinical-stage biopharmaceutical company and the employee headcount will be cut by at least 25 percent by the end of 2022.
Belgium’s UCB is acquiring California-based Zogenix, a company focused on rare diseases, in a deal valued up to €1.7 billion ($1.9 billion).
More than 1.2 million people died in 2019 from infections caused by bacteria resistant to multiple antibiotics, higher than HIV/AIDS or malaria, according to a new report published on January 20.
Engitix Therapeutics raised $54 million in Series A financing. Engitix plans to use the money to boost the company’s drug discovery pipeline in fibrosis and cancer and expand its team, facilities and operations.
When used in children, rapid antigen tests for detecting the coronavirus do not meet accuracy criteria set by the World Health Organization and U.S. and UK device regulators, according to researchers who reviewed 17 studies of the tests. Other research appears to confirm smaller, earlier studies that suggested nursing mothers are unlikely to transmit the coronavirus in breastmilk.
Ceptur Therapeutics – based in Hillsborough, NJ, Philadelphia and Copenhagen – closed on a Series A financing round worth $75 million.
Valneva said on January 19 that preliminary studies showed three doses of the French biotech firm’s inactivated COVID-19 vaccine candidate neutralized the Omicron variant of the disease.
ImmunityBio shared interim results from the company’s ongoing metastatic pancreatic cancer trial, demonstrating overall survival that is double the historical rate.